Achilles Therapeutics plc Quarterly Nonoperating Income (Expense) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Achilles Therapeutics plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2022 to Q2 2024.
  • Achilles Therapeutics plc Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $1.43M, a 17.7% increase year-over-year.
  • Achilles Therapeutics plc annual Nonoperating Income (Expense) for 2023 was $6.08M, a 16.9% decline from 2022.
  • Achilles Therapeutics plc annual Nonoperating Income (Expense) for 2022 was $7.32M, a 134% increase from 2021.
  • Achilles Therapeutics plc annual Nonoperating Income (Expense) for 2021 was $3.13M, a 490% increase from 2020.
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.43M +$215K +17.7% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-14
Q2 2023 $1.21M -$2.06M -62.9% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-14
Q2 2022 $3.27M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.